SEC Form 4 · accession 0001209191-19-018984
Crinetics Pharmaceuticals, Inc. · CRNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard Scott Struthers
Officer — President & CEO · Director
Period of report
Mar 8, 2019
Accepted (ET)
Mar 12, 2019 · 6:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001658247
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $25.19 | Mar 8, 2019 | A | 176,250 | A | — | Mar 7, 2029 | Common Stock | 176,250 | 176,250 | D |
Explanation of responses
- F1The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the Vesting Commencement Date of March 8, 2019.
Remarks
Exhibit 24 - Power of Attorney